Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

MJ08-First-Person
ND14-Careers
JF04-Editor
Billing for Off-Label Drugs Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Billing for Off-Label Drugs Peg Skelly To cite this article: Peg Skelly (1999) Billing for Off-Label …
Organizing care around a patient’s diagnosis with multidisciplinary, disease-specific teams is value-based healthcare delivery.
Succumbing to a Sheathed Sword Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Succumbing to a Sheathed Sword James L. Wade III To cite this article: James L. Wade III (1997) Succumbing …
ND05-First-Person
ND12-An-innovative-arts-in-medicine-program
SO03-Editor
JF05-Online-eHealth- Research
The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care communi- ty. Founded in 1974, ACCC is a powerful network of 25,000 multidisciplinary practitioners from 2,100 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve—so has ACCC—adapt- …
ND08-Hospital-&-Medical-Oncology-Practice-Integration
Financial Advocacy Boot Camp Two sets of dynamic online courses offer the tools your staff needs to help patients pay for treatment—while maximizing reimbursement at your program. Shape up your team's skills with introductory courses, and just launched this month, an advanced 2.0 set of online courses. Explore Online Courses Financial Advocacy Census Survey ACCC would like to better understand …
tools 75 OI | Vol. 38, No 3, 2023 | accc-cancer.org approved the single-dose, prefilled autoinjector presentation of Udenyca® (pegfilgrastim-cbqv), a biosimilar of Neulasta® (pegfilgrastim) (Amgen, amgen.com). • On March 3, the FDA approved Verzenio® (abemaciclib) (Eli Lilly and Company, lilly.com) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for …
21-Northwest-Community-Healthcare-Screening-Chart-Documentation
Survivorship-An-Update-on-Survivorship-Education-for-Quality-Cancer-Career
Arizona-Oncology-In-Office-Dispensing-Process
tools 22 OI | Vol. 38, No 1, 2023 | accc-cancer.org Approved Drugs • On November 10, the U.S Food and Drug Administration (FDA) approved Adcetris® (brentuximab vedotin) (Seagen, seagen. com) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high-risk classical …
Benefits of Membership Industry Advisory Council members receive a variety of benefits, including recognition through the ACCC network and better visibility with the nationwide cancer care community. Join the Industry Advisory Council and you will: Receive timely updates on current legislative and regulatory issues Gain direct contact with key oncology decision makers Gain access to a …